Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of Cimzia in pediatric Crohn's disease after C87035
2017-005025-20Phase 2
- Sponsor
- UCB
- Start
- Mar 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Number of subjects reporting at least one treatment-emergent adverse event.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-005025-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005025-20.